Dennis Vargo | Global Safety Lead
Takeda Pharmaceutical Company

Dennis Vargo, Global Safety Lead, Takeda Pharmaceutical Company

Appearances:



Day One World Drug Safety Congress EU 2018 @ 13:35

“Orphanizing” NSCLC: Subsetting for more targeted, more effective and less toxic therapies: EGFR and ALK

  • Chemotherapy for NSCLC
  • NSCLC subsets (EGFR and ALK)
  • Targeted therapy for NSCLC subsets: efficacy, toxicity, class effects
last published: 13/Aug/18 10:55 GMT

back to speakers